Clinical Perspectives

FDA Approval of Percutaneous Hepatic Perfusion Offers Patients New Hope

The FDA recently approved Percutaneous Hepatic Perfusion (PHP) with the HEPZATO KIT to treat metastatic uveal melanoma.

FDA Approves New Gene Therapy for Synovial Sarcoma

The FDA granted accelerated approval for Tecelra (afamitresgene autoleucel), a groundbreaking gene therapy for metastatic synovial sarcoma.

Q&A: Insights on Oral Cavity Cancer Treatment

Due to their aggressive nature, it's crucial to have treatment by an experienced surgeon and a multidisciplinary team from the first diagnosis of...

Minimally Invasive Surgery Advancements for Spinal Tumor Surgery

The Minimally Invasive Spine Oncology (MISO) program is patient-centered with a focus on the use of minimal access techniques for the treatment of...

Recent FDA Approvals for New Uses of Cellular Therapies

Recent advancements in cellular therapies, such as CAR T and TILs, have led to new FDA approvals for expanded uses.

Breakthroughs in Bispecific Antibodies & T-Cell Engagers: A New Era in Cancer Treatment

Bispecific T-cell engagers (BiTEs), a specialized subtype of bispecific antibodies (BsAbs), are antibody-based structures engineered to engage...

The Critical Role of Primary Care Physicians in Identifying Hematologic Malignancies

Multiple myeloma is a rare type of cancer that affects plasma cells, a type of white blood cell found in bone marrow that makes antibodies to help...

Q&A: Geniculate Artery Embolization (GAE)

GAE can be highly beneficial for patients who are not suitable candidates for joint replacement surgery.

Rectal Cancer Preservation: Balancing Cure and Quality of Life

The multidisciplinary team at Moffitt reviews every newly diagnosed rectal cancer within a specialized Rectal Cancer Tumor Board.

Understanding Mutations in the RAS Family of Genes

Moffitt has a strong interest to develop new therapies that can help patients with RAS mutations. 

Genitourinary Oncology Advancement Update from ASCO 2024

Dr. Monica Chatwal, in the Genitourinary Oncology Department, shared some of the exciting treatments for genitourinary cancers at ASCO 2024.

Moffitt Researchers Investigating CAR T Therapy Feasibility in Metastatic Castration-resistant Prostate Cancer

Dr. Jingsong Zhang is leading a phase I trial of an infusion of autologous gamma delta T cells genetically engineered with a CAR T to target the...

Emerging Therapeutic Landscape in Genitourinary Oncology

The field of genitourinary (GU) oncology has witnessed a paradigm shift with the advent of pioneering therapies for prostate, bladder, kidney,...

Surgical Expertise Only at Moffitt

The surgical teams at Moffitt have unparalleled skills and are familiar with treating and studying even the rarest cancers.  

Insights on the Management of Glioma Patients and Treatment Innovations

The glioma landscape, particularly those with the H3 K27M mutation, presents unique challenges and opportunities for patient management and treatment...